ArticleClinical and experimental dermatology2022
Cost-effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria.
Sarah Denman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this paperpooled itcites it